Journal of Investigational Allergology and Clinical Immunology最新文献

{"title":"Emerging Allergen Immunotherapy Approaches: Impact on Intradermal and Subcutaneous Strategies in Food Allergy Treatment.","authors":"Charlotte Castenmiller, Ronald van Ree","doi":"10.18176/jiaci.1130","DOIUrl":"10.18176/jiaci.1130","url":null,"abstract":"<p><p>Food allergy has emerged as a significant global health concern, impacting quality of life and contributing to rising health care costs. Severe allergic reactions can be life-threatening and, in some cases, require hospitalization. Standard care typically involves elimination diets and epinephrine injections upon accidental exposure. In the past decade, oral immunotherapy has proven to be effective in reducing symptoms of severe food allergies. However, it also has limitations, including long treatment durations and risk of severe adverse effects. Therefore, alternative therapies are being explored. These include intradermal and subcutaneous injections of novel hypoallergenic allergen immunotherapy (AIT) formulations, such as chemically modified allergens, T-cell epitope-based therapies, particulate-based strategies, and DNA vaccines. The present review will examine the potential of intradermal and subcutaneous AIT applications and provide an overview of current developments in these innovative AIT strategies.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145758217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desensitization to Acyclovir: A Case Report.","authors":"Sofia Carreras-Katcheff, Arnau Salvany-Pijuan, Mar Guilarte, Victoria Cardona, Javier Pereira-González","doi":"10.18176/jiaci.1114","DOIUrl":"10.18176/jiaci.1114","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"66-67"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers of Tolerance to Baked Milk in Cow's Milk-Allergic Children at High Risk of Anaphylaxis.","authors":"Olga Domínguez, Carmen Riggioni, Elisabet Poyatos, Rosa M Jiménez-Feijoo, Monica Piquer, Adriana Machinena, Mar Folqué, Iñaki Ortiz de Landazuri, Maria Torradeflot, Jaime Lozano, Laia Alsina, Mariona Pascal, Montserrat Alvaro-Lozano","doi":"10.18176/jiaci.1074","DOIUrl":"10.18176/jiaci.1074","url":null,"abstract":"<p><strong>Background and objectives: </strong>Consuming baked milk (BM) may accelerate tolerance in cow's milk-allergic (CMA) children. In high-risk patients, controlled BM-based oral food challenge (BM-OFC) is recommended, as the benefits can outweigh the risks of a prolonged exclusion diet. Objectives: To identify predictive biomarkers for BM-OFC outcomes in a cohort at high risk of anaphylaxis and compare the OFC thresholds for baked and pasteurized cow´s milk protein (CMP).</p><p><strong>Methods: </strong>We performed a prospective study of children (≥12 months to <6 years) with a history of CMA. Testing at diagnosis involved prick testing, specific IgE (sIgE) for CM and components, sIgG4, and the basophil activation test (BAT). Patients underwent a BM-OFC aiming for a cumulative dose of 1 g of CM protein. BM-tolerant children subsequently underwent a CM-OFC to confirm CMA.</p><p><strong>Results: </strong>The study population comprised 50 patients (66% with a history of anaphylaxis). A reaction was recorded during BM-OFC in 36% of patients (39% with anaphylaxis). The median reactivity threshold was 138 mg of CMP. Risk factors for BM allergy included history of anaphylaxis, age >3 years, elevated CM-sIgE and casein-sIgE, and a positive BAT result. The cut-offs were as follows: >5 mm for skin prick testing with casein, ≥8.5 kUA/L for CM-sIgE, and ≥5.7 kUA/L for casein-sIgE. These made it possible to distinguish BM-allergic patients from CMA patients who tolerated BM. Among BM-tolerant patients, the CM-OFC threshold was 270 mg, with 43.8% reacting to <100 mg (40% with anaphylaxis).</p><p><strong>Conclusions: </strong>BM-OFC is not risk-free. Nevertheless, two-thirds of high-risk CMA children were BM-tolerant and benefited from early introduction of BM products. Patient selection can be guided by biomarkers and a prior history of anaphylaxis to baked goods. The reactivity threshold to pasteurized milk was less than half of the tolerated dose of BM (1000 mg).</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"36-46"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Dual Super-Response in Patients With Asthma and CRSwNP Treated With Mepolizumab.","authors":"Miguel Estravís, David Carreiras-Quintas, Juan C Triviño, Jacqueline Pérez-Pazos, María Gil-Melcón, Asunción García-Sánchez, Jacinto Ramos, Manuel Gómez-García, Emma Moreno-Jimenez, Natalia Morgado, Cristina Martín-García, Francisco J Muñoz-Bellido, Elena Curto, Catalina Sanz, María Isidoro-García, Ignacio Dávila","doi":"10.18176/jiaci.1102","DOIUrl":"10.18176/jiaci.1102","url":null,"abstract":"<p><strong>Background: </strong>Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are both type 2 (T2) inflammatory diseases that frequently co-occur and are interconnected through shared immunological pathways. The anti-IL-5 monoclonal antibody mepolizumab has shown efficacy in reducing eosinophilic inflammation and improving clinical outcomes. However, the molecular mechanisms underlying response to treatment, particularly at the transcriptomic level, remain underexplored. We aimed to investigate peripheral blood transcriptomic changes and identify potential biomarkers associated with dual super-response to mepolizumab in patients with severe asthma and CRSwNP.</p><p><strong>Methods: </strong>The study population comprised 29 participants (19 patients with severe asthma and CRSwNP and 10 healthy controls). Whole blood RNA sequencing was performed before and after treatment with mepolizumab in 6 patients, followed by validation of candidate genes using qPCR. Clinical responses were assessed using the FEOS score (FEV1, exacerbations, oral corticosteroids, symptoms) and lung function measurements, and the 22-item Sino-Nasal Outcome Test (SNOT-22) score.</p><p><strong>Results: </strong>Mepolizumab significantly improved clinical parameters, including exacerbation rates, asthma control, and the SNOT-22 score. Transcriptomic analysis identified 156 differentially expressed genes after treatment with mepolizumab, significantly enriching immune and inflammatory pathways. Twelve candidate genes were studied. Three of these genes (PNPLA1, C3AR1, and RGS1) were validated as potential predictors of super-response to treatment of asthma and CRSwNP. Baseline expression levels of RGS1 were associated with dual super-response in asthma and CRSwNP.</p><p><strong>Conclusion: </strong>This study provides new insights into transcriptomic changes following mepolizumab treatment and highlights RGS1 as a potential biomarker for predicting dual super-response in asthma and CRSwNP. Our findings contribute to precision medicine approaches and support the identification of optimal candidates for anti-IL-5 therapy.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"47-60"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omalizumab as Premedication for Hypersensitivity Reactions Refractory to Asparaginase Desensitization in Children With Acute Lymphoblastic Leukemia.","authors":"Teodorikez-Wilfox Jimenez-Rodriguez, Angela Rico Rodes, Amparo Burgos San Jose, María Del Cañizo Moreira, Laura Ureña Horno, María E Valerio Alonso, Andrea Cano Rodriguez, Clara P Gallego Velez, María P González Delgado, María Tasso Cereceda","doi":"10.18176/jiaci.1118","DOIUrl":"10.18176/jiaci.1118","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"70-72"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catalase and Hypersensitivity to Avocado.","authors":"Öner Özdemir","doi":"10.18176/jiaci.1128","DOIUrl":"10.18176/jiaci.1128","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"80-81"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145670724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter Regarding \"Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Induced by Meropenem in a Patient Under Therapy With Avelumab and Subsequent Flare-up\".","authors":"Joshua Aulenbacher, Maja Mockenhaupt, Tilo Biedermann, Knut Brockow","doi":"10.18176/jiaci.1141","DOIUrl":"10.18176/jiaci.1141","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"83-84"},"PeriodicalIF":6.6,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145967727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Cross-Reactive Allergens in Mushroom Allergy: A Case Report in a 17-Year-Old Girl in Japan.","authors":"Makoto Nojo, Shintaro Suzuki, Tomoki Uno, Yoshitaka Uchida, Yoshito Miyata, Hironori Sagara, Akihiko Tanaka","doi":"10.18176/jiaci.1125","DOIUrl":"10.18176/jiaci.1125","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"74-76"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Competent Allergists Facing the Challenges of the 21st Century: Multidisciplinary Management, Commitment to Excellence, Effective Communication, and Quality Teaching.","authors":"Darío Antolín-Amérigo, Leticia de Las Vecillas, Alberto Alvarez-Perea, Beatriz Núñez-Acevedo, Ana González Moreno, Beatriz Rodríguez Jiménez, Gabriela Zambrano Ibarra, Ignacio Esteban-Gorgojo, Sonia Vázquez Cortés, Jesús Macías Iglesias, Vanesa Sánchez-Moreno, Tomás Chivato","doi":"10.18176/jiaci.1119","DOIUrl":"10.18176/jiaci.1119","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"61-63"},"PeriodicalIF":4.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Human Monoclonal Antibody Displays Promiscuous Binding to Multiple Type 1 nsLTP Allergens.","authors":"Gage O Leighton, Lars C Pedersen, Jungki Min, Paige Creeks, Scott A Gabel, Lalith Perera, Thomas A Randall, Robert M Petrovich, Robert G Hamilton, Derek Croote, Geoffrey A Mueller","doi":"10.18176/jiaci.1143","DOIUrl":"10.18176/jiaci.1143","url":null,"abstract":"<p><strong>Background and objectives: </strong>Nonspecific lipid transfer proteins (nsLTPs) are frequently cross-reactive allergens that hamper diagnosis and avoidance. It is challenging to distinguish cross-reactivity from cosensitization with polyclonal serum owing to the presence of a few promiscuous antibodies or many highly specific antibodies. Objective: We hypothesized that a robust analysis of more human monoclonal antibodies (mAbs) would enable us to compare crossreactivity with cosensitization.</p><p><strong>Methods: </strong>Human monoclonal antibodies were cloned from allergic patients via single cell sequencing and screened for affinity to extracts and recombinant allergens. Ara h 9 was expressed and crystallized with the mAb IGX-3103. Affinity for nsLTPs was explored using molecular modeling, site-directed mutagenesis, and ELISA.</p><p><strong>Results: </strong>A human IgG4 mAb named IGX-3103 was discovered from a type 2-polarized memory B cell expressing CD23, IL-4Ra, and germline IGHE. IGX-3103 bound to 19 different type 1 nsLTP allergens and to extracts from sources without a characterized nsLTP allergen. The structure showed that IGX-3103 induced a conformational change in Ara h 9, enabling a hydrophobic residue from the antibody, Phe104, to enter the lipid binding cavity. Key residues in the epitope were identified to include Leu1, Ser2, Cys3, Lys39, and Asp43 in Ara h 9; these residues are conserved across type 1 nsLTPs, thus explaining the promiscuity of IGX-3103.</p><p><strong>Conclusions: </strong>IGX-3103 is an example of a human mAb with cross-reactivity to pollen, fruit, and seed type 1 nsLTPs. This observation anecdotally supports the possibility that a few promiscuous mAbs could be driving cross-reactivity.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":4.8,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12888792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}